Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia

NCT01249664 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT01249664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01249664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase-3, Multi-center, Randomized, Double-masked, Sham-controlled Study of the Efficacy, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects With Choroidal Neovascularization Secondary to Pathologic Myopia
Lead sponsor
Bayer
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2010
Completion date
August 31, 2013
Enrollment
122 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

myopia, pathological